Growing GiveWell’s Largest Research Area: Malaria

Key Takeaways

• GiveWell has spent over $1 billion on malaria prevention, saving ~235k lives
• Malaria research team now 15 members, >20,000 hours annually
• New studies assess net durability, SMC dose adherence, and drug efficacy
• Grants target net-use behavioral barriers and expand SMC in East Africa
• Evidence-driven grants aim to refine cost‑effectiveness and guide future funding

Pulse Analysis

Malaria remains a leading cause of mortality worldwide, claiming around 600,000 lives each year, with 70% of deaths occurring in African children under five. Charitable donors have long looked to high‑impact, data‑driven organizations to maximize the health return on every dollar. GiveWell, a prominent evaluator of effective‑giving opportunities, has leveraged its analytical rigor to channel more than $1 billion into proven malaria tools such as insecticide‑treated nets and seasonal malaria chemoprevention (SMC). The organization’s track record of estimating over 235,000 lives saved underscores the scale of its influence and sets a benchmark for cost‑effectiveness in global health philanthropy.

In the past few years, GiveWell’s malaria research unit has doubled in size, now employing 15 specialists who collectively log over 20,000 research hours per year. This expanded capacity is being used to fill critical evidence gaps: field studies in Nigeria, Cameroon, and the Democratic Republic of Congo are measuring how long new dual‑insecticide nets retain efficacy, while independent coverage surveys in Burkina Faso compare caregiver‑reported SMC adherence with blood‑sample drug levels. Parallel behavioral research, funded in partnership with the Behavioural Insights Team, probes why only about 63% of distributed nets are actually hung, testing interventions such as color‑coded nets and social‑norm messaging. These granular data streams enable GiveWell to refine its cost‑effectiveness models, ensuring that future grants target the most impactful levers.

The strategic payoff of this evidence‑first approach extends beyond better metrics. By validating net usage and SMC adherence, GiveWell can advise donors on where incremental funding yields the greatest marginal lives saved, potentially unlocking new resources for under‑served regions in East and Southern Africa. Moreover, the organization’s recent investment in a large‑scale randomized trial of alternative drug regimens in Malawi could broaden the geographic reach of SMC, addressing drug‑resistance concerns. As GiveWell continues to expand its portfolio—exploring primaquine for transmission reduction and other emerging interventions—its rigorous, data‑driven methodology positions it as a pivotal conduit for high‑impact malaria philanthropy, guiding billions of dollars toward the most life‑saving outcomes.